Anacor Pharma Allies With TB Alliance to Explore Novel Anti-Bacterial Drug Target for TB Therapy

Wed, 05/27/2009 - 4:27am
Anacor Pharmaceuticals has entered into a license and research agreement with not-for-profit Global Alliance for TB Drug Development (TB Alliance) to explore a novel anti-bacterial drug target for use in tuberculosis (TB) therapy. Under the agreement, Anacor will provide the TB Alliance with a non-exclusive, royalty-free worldwide license for TB. Anacor will receive support from the TB Alliance for its prominent role in the joint research efforts. Anacor also announced today that it has extended an existing license and drug development agreement with not-for-profit, Drugs for Neglected Diseases initiative (DNDi) to develop new therapeutics for Human African Trypanosomiasis (HAT or African Sleeping Sickness), Visceral Leishmaniasis (kala azar) and Chagas disease. Under the terms of the agreement, Anacor will provide DNDi with a non-exclusive, royalty-free license for any boron-based therapeutics for neglected diseases identified through the collaboration for developing world countries. "Anacor is committed to applying our boron chemistry platform to the development of new therapies for the treatment of neglected diseases," said David Perry, Chief Executive Officer of Anacor Pharmaceuticals, Inc. "Funds from public-private partnerships like the TB Alliance and DNDi make it possible to meet both our responsibilities to our shareholders and help reduce the burden of neglected diseases. As these programs are successful, we hope to expand our current efforts and establish programs in new disease areas." "Our agreement with Anacor underscores our commitment to seek innovative scientific approaches with the potential to assist in the fight against tuberculosis," says Dr. Mel Spigelman, President and Chief Executive Officer of the TB Alliance. "Tuberculosis was responsible for nearly 1.8 million deaths in 2007 - approximately, one person every 20 seconds - and there is a significant need for novel medications to combat growing bacterial resistance to current drugs and to reduce the duration and complexity of therapy. Anacor represents the spirit of innovation we value in this arena, and we look forward to working together to identify new treatments for this devastating disease." "This collaboration between DNDi and Anacor addresses a critical gap in the drug development pipeline for these neglected diseases, which is the selection of new drug candidates to enter into further development," remarked Dr. Shing Chang, R&D Director of DNDi. "As we continue our partnership with Anacor to bring some of the best scientific resources to address the needs of the most neglected patients, we're encouraged by the excellent results and the rapid pace of our discovery efforts, which have moved from hit to a lead series in 12 months." To oversee Anacor's efforts in this area, the company has appointed Eric Easom to the newly created position of Program Leader, Neglected Diseases, and he will serve as its liaison to public and private partners. Mr. Easom brings 19 years of pharmaceutical, biotech and non-profit experience to Anacor. The majority of his career was spent at Eli Lilly and Company where he served in a variety of commercial, business development and manufacturing roles. He has also held business development and commercial roles at InteKrin Therapeutics, MedImmune and McKesson. Mr. Easom has spent a number of years actively working with not-for-profits focused on neglected diseases and currently serves as Vice Chair of the Board for the Seattle-based Infectious Disease Research Institute. Mr. Easom holds an MBA from Indiana University and bachelor and master's degrees from the University of Louisville.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.